Technology

Eye Catching Stock: Cellular Biomedicine Group Inc. (NASDAQ:CBMG)

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) stock observed trading -12.26% off 52-week high price. On the other end, the stock has been noted 64.85% away from low price over the last 52-weeks. The stock disclosed a move of 29.03% away from 50 day moving average and 15.00% away from 200 day moving average. Moving closer, we can see that shares have been trading 19.80% off 20-day moving average. It has market cap of $367.61M.

On Oct. 30, 2019, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, declared that it will release its financial results for the third quarter ended September 30, 2019 after the market closes on Wednesday, November 6, 2019.

About Cellular Biomedicine Group

Cellular Biomedicine Group (NASDAQ:CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company’s GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a Joint Laboratory of Cell Therapy with GE Healthcare and a Joint Cell Therapy Technology Innovation and Application Center with Thermo Fisher Scientific, which partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) accepted the Company’s IND application for a Phase II trial for AlloJoin®, CBMG’s Off-the-Shelf allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and the Company’s IND application for a Phase II trial for ReJoin® autologous haMPC therapy for the treatment of KOA. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index.

 The USA based company Cellular Biomedicine Group moved with change of -0.22% to $18.1 with the total traded volume of 77357 shares in recent session versus to an average volume of 31.75K. The stock was observed in the 5days activity at 18.07%. The one month performance of stock was20.67%. CBMG’s shares are at 29.84% for the quarter and driving a 41.63% return over the course of the past year and is now at 2.49% since this point in 2018.  Right now the stock beta is 2.9. The average volatility for the week and month was at 5.38% and 4.09% respectively. There are 20.31M shares outstanding and 13.2M shares are floated in market.

Leave a Reply

Your email address will not be published. Required fields are marked *